Home › Ernstige depressieve stoornis › Arkansas › Little Rock
Ernstige depressieve stoornis klinische studies in Little Rock, AR
14 studies voor Ernstige depressieve stoornis zoeken deelnemers op locaties in en rond Little Rock (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
RekruterenFase 3
- Preferred Research Partners, Inc., Little Rock
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
RekruterenFase 3
- SanRo Clinical Research Group LLC WCG Clinical Network, Bryant · 15 mijl verwijderd
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
RekruterenFase 3
- SanRo Clinical Research Group LLC WCG Clinical Network, Bryant · 15 mijl verwijderd
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
RekruterenFase 3
- Vanda Investigational Site, Little Rock
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RekruterenFase 4
- Neurocrine Clinical Site, Bryant · 15 mijl verwijderd
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
RekruterenFase 3
- SanRo Clinical Research Group, Bryant · 15 mijl verwijderd
A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
RekruterenFase 2
- Draig Clinical Site, Little Rock
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
RekruterenFase 2
- Draig Clinical Site, Little Rock
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RekruterenFase 3
- Neurocrine Clinical Site, Bryant · 15 mijl verwijderd
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
RekruterenFase 3
- Woodland International Research Group, Little Rock
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RekruterenFase 3
- Neurocrine Clinical Site, Little Rock
- Neurocrine Clinical Site, Bryant · 15 mijl verwijderd
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
RekruterenFase 2
- Preferred Research Partners /ID# 279206, Little Rock
- Woodland International Research Group /ID# 277605, Little Rock
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
RekruterenFase 2
- Pillar Clinical Research, LLC, Little Rock
- Preferred Research Partners, Inc., Little Rock
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RekruterenFase 3
- Neurocrine Clinical Site, Little Rock
Ernstige depressieve stoornis studies in andere steden
- New York City, NY36 studies
- Boston, MA31 studies
- Atlanta, GA25 studies
- Philadelphia, PA23 studies
- Orlando, FL19 studies
- Miami, FL18 studies
- Chicago, IL17 studies
- Tampa, FL17 studies
- San Diego, CA16 studies
- Houston, TX16 studies
- Austin, TX13 studies
- Las Vegas, NV13 studies
Andere studies in Little Rock
- Schizofrenie19 studies
- Kanker (alle vormen)14 studies
- Acute myeloïde leukemie13 studies
- Niet-kleincellige longkanker13 studies
- Obesitas11 studies
- Endometriumkanker10 studies
- Depressie10 studies
- Type 2-diabetes10 studies
- Longkanker9 studies
- Cardiovasculaire ziekte9 studies
- Blasenkanker9 studies
- Hartfalen9 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.